We herein describe a 70-year-old woman who presented with respiratory failure due to extensive lung adenocarcinoma. Despite advanced disease, care in the intensive care unit with ventilator support was performed because she was a newly diagnosed patient and was considered to have the potential to recover after cancer treatment. Because prompt control of the cancer was needed to treat the respiratory failure, empirical treatment with an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor was initiated before confirmation of EGFR-mutant adenocarcinoma, and the patient was successfully treated. Later, EGFR-mutant adenocarcinoma was confirmed.
■ Case Report ■ Lung cancer is the leading cause of cancer mortality worldwide. [1] Patients with lung cancer often require care in the intensive care unit (ICU) for cancer-or treatment-related complications. [2] Despite recent improvement in the intensive care of patients with lung cancer, the treatment outcome, especially with mechanical ventilator support, remains extremely poor. [3] Therefore, aggressive care for patients with advanced lung cancer is controversial. [4] However, a recent study advocated that ICU trials should include patients with newly diagnosed cancers, but with a life expectancy of less than 1 year, because they may have a chance to recover after cancer treatment. [5] Erlotinib, a reversible and specific tyrosine kinase inhibitor (TKI), is effective in tumors with gene mutations that activate the epidermal growth factor receptor (EGFR). [6] Previous studies have shown that lung adenocarcinoma among East Asian female never-smokers or former light smokers was associated with a higher probability of having an EGFR mutation. [7, 8] About 80% of lung adenocarcinoma from East Asian never-smokers harbored an EGFR kinase mutation. [9, 10] Sex, ethnic origin, smoking status, and histologic findings help to identify patients who have a high likelihood of responding to EGFR-TKI treatment. [7] We recently encountered a patient with extensive lung adenocarcinoma causing respiratory failure. Despite advanced disease, care in the ICU with ventilator support was performed because she was a newly diagnosed patient and EGFR mutation was highly suspected. Empirical erlotinib treatment resulted in an improvement in the disease and allowed ventilator weaning.
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( Fig. 2A, B and C) and month 9 of treatment (Fig. 3A, B and C), showed a dramatic decrease in the extent of the primary mass and multiple metastatic lesions in the lung. Chest radiography and CT performed at month 18 of treatment showed a slightly increased extent of the disease (Fig. 4A , B and C). However, her symptoms were stable, and she was continuing to take erlotinib at the time of this writing.
Discussion
Patients with newly diagnosed cancer may require ICU admission and immediate chemotherapy to treat acute lifethreatening organ failure caused by the cancer. Because immediate treatment of the malignancy is the only way to ensure recovery, these patients must receive immediate anticancer therapy as well as life-sustaining therapies. [12] We have reported a case of newly diagnosed lung cancer causing respiratory failure. Because the patient's clinical situation was too serious to wait for the results of pathology and gene mutation analysis, we initiated empirical treatment with an oral EGFR TKI based on clinical information including ethnic origin, sex, and smoking history, and the treatment outcome was very successful. After initiation of treatment, we confirmed the EGFR mutation.
As in this case, a previous report of empirical erlotinib treatment in a patient who presented with respiratory failure secondary to lung adenocarcinoma with a high likelihood of having an EGFR mutation suggested a "shoot first, ask later" strategy. We previously described three critically ill patients with advanced lung cancer who required mechanical ventilation for respiratory failure and were successfully treated with ALK inhibitors. [14] While our patient required 62 days to be weaned off the mechanical ventilator, it took 17 to 42 days to wean the patients off the ventilator in previous cases. Although a considerable time was needed in both cases, all patients were successfully treated. These cases suggest that physicians require a new perspective on the use of a molecular targeted agent in the ICU and treatment for lung cancer patients with respiratory failure caused by pretreated lung cancer.
In conclusion, our case shows that respiratory failure induced by extensive lung adenocarcinoma can be successfully reversed by a targeted therapy. Our case suggests that there is a population of patients with newly diagnosed primary lung cancer who are likely to benefit from targeted therapy, although they initially require ICU support.
